monoclonal antibodies

Question 1

what is a monoclonal antibody?

Answer 1

targets extracellular patways

Question 2

Common side effects on monoclonal antibodies?

Answer 2

Varies

Question 3

Ibritumomab tiuxetan (Zevalin)

Answer 3

IV

Target: CD20

Relapsed or refractory B-cell NHL

Side effects: possible infusion reaction, M,N,V, asthenia, infections, cough, dyspnea, sinusitis

Question 4

Rituximab (rituxan)

Answer 4

IV

Target: CD20

B-cell NHL, CLL

Side effects: possible infusion reaction, tumor lysis syndrome, skin reactions, M,N,V

Question 5

Pertuzumab (perjeta)

Answer 5

IV

Target: HER2/neu

metastatic breast

Side effects: poss infusion reaction, cardiotoxicity, fatigue

Question 6

Trastuzumab (herceptin)

Answer 6

IV

Target: HER2/neu

breast, metastatic gastric

Side effects: poss infusion reaction, N,V,D, cardiotoxicity, pulmonary toxicity, myelosuppression

Question 7

Ado-trastuzumab emtansine (Kadcyla)

Answer 7

IV

Target: HER2/neu

metastatic breast

Side effects: poss infusion reaction, cardiotoxicity, pulmonary toxicity, hepatotoxicity, thrombocytopenia, peripheral neuropathy, constipation

Question 8

Cetuximab (etbitux)

Answer 8

IV

Target: EGFR

Colorectal, HN

Side effects: poss infusion reaction, acneiform skin rash, pruritis, pulmonary toxicity, hypomagnesmia, malaise, asthenia, N,V,D, anorexia

Interactions: monitor serum magnesium, especially if also received oxalipatin

Question 9

Panitumumab (Vectibix)

Answer 9

IV

Target: EGFR

Colorectal

Side effects: poss infusion reaction, acneiform skin rash, pruritis, pulmonary toxicity, hypomagnesmia, malaise, D

Interactions: monitor serum magnesium

Question 10

Denosumab (xgeva)

Answer 10

IV

Target: RANKL

bone mets

Side effects: N,V,D, hypocalcemia, osteonecrosis of jaw

Question 11

Denosumab (prolia)

Answer 11

IV

Target: RANKL

patients with osteoporosis at high risk of fracture

Side effects: N,V,D, hypocalcemia, osteonecrosis of jaw